PMID- 34948350
OWN - NLM
STAT- MEDLINE
DCOM- 20220118
LR  - 20220518
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 24
DP  - 2021 Dec 17
TI  - What Is the Role of HLA-I on Cancer Derived Extracellular Vesicles? Defining the 
      Challenges in Characterisation and Potential Uses of This Ligandome.
LID - 10.3390/ijms222413554 [doi]
LID - 13554
AB  - The Human Leukocyte Antigen class I (HLA-I) system is an essential part of the 
      immune system that is fundamental to the successful activation of cytotoxic 
      lymphocytes, and an effective subsequent immune attack against both 
      pathogen-infected and cancer cells. The importance of cytotoxic T cell activity 
      and ability to detect foreign cancer-related antigenic peptides has recently been 
      highlighted by the successful application of monoclonal antibody-based checkpoint 
      inhibitors as novel immune therapies. Thus, there is an increased interest in 
      fully characterising the repertoire of peptides that are being presented to 
      cytotoxic CD8+ T cells by cancer cells. However, HLA-I is also known to be 
      present on the surface of extracellular vesicles, which are released by most if 
      not all cancer cells. Whilst the peptide ligandome presented by cell surface HLA 
      class I molecules on cancer cells has been studied extensively, the ligandome of 
      extracellular vesicles remains relatively poorly defined. Here, we will describe 
      the current understanding of the HLA-I peptide ligandome and its role on 
      cancer-derived extracellular vesicles, and evaluate the aspects of the system 
      that have the potential to advance immune-based therapeutic approaches for the 
      effective treatment of cancer.
FAU - Boyne, Caitlin
AU  - Boyne C
AD  - School of Medicine, University of St. Andrews, St. Andrews KY16 9TF, UK.
FAU - Lennox, Debra
AU  - Lennox D
AD  - School of Medicine, University of St. Andrews, St. Andrews KY16 9TF, UK.
FAU - Beech, Olivia
AU  - Beech O
AUID- ORCID: 0000-0002-9038-2916
AD  - School of Medicine, University of St. Andrews, St. Andrews KY16 9TF, UK.
FAU - Powis, Simon J
AU  - Powis SJ
AD  - School of Medicine, University of St. Andrews, St. Andrews KY16 9TF, UK.
FAU - Kumar, Pankaj
AU  - Kumar P
AD  - School of Medicine, University of St. Andrews, St. Andrews KY16 9TF, UK.
LA  - eng
GR  - MR/V035851/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20211217
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - *Extracellular Vesicles
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Mass Spectrometry
MH  - Neoplasms/immunology/*metabolism/physiopathology/therapy
MH  - *T-Lymphocytes, Cytotoxic
PMC - PMC8703738
OTO - NOTNLM
OT  - HLA-1
OT  - antigen presentation
OT  - cancer immunology
OT  - extracellular vesicles
OT  - immunopeptidome
OT  - mass spectrometry
COIS- The authors declare no conflict of interest.
EDAT- 2021/12/25 06:00
MHDA- 2022/01/19 06:00
PMCR- 2021/12/17
CRDT- 2021/12/24 01:17
PHST- 2021/12/02 00:00 [received]
PHST- 2021/12/13 00:00 [accepted]
PHST- 2021/12/24 01:17 [entrez]
PHST- 2021/12/25 06:00 [pubmed]
PHST- 2022/01/19 06:00 [medline]
PHST- 2021/12/17 00:00 [pmc-release]
AID - ijms222413554 [pii]
AID - ijms-22-13554 [pii]
AID - 10.3390/ijms222413554 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Dec 17;22(24):13554. doi: 10.3390/ijms222413554.